Please assess the completion status of the following clinical trial:

Trial Title: Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patient;~* Diagnosed in one of the participating centers with at least one pelvic mass that is suspected to be of ovarian origin;~* Are to undergo surgery in order to obtain a final histological diagnosis;~* 18 years of age or older.~Exclusion Criteria:~* Pregnant patients;~* Patients aged under 18 years;~* Patients in whom the surgery does not take place, or takes place more than 120 days after RMI and simple ultrasound-based rules are performed;~* Patients with a prior bilateral oophorectomy;~* Patients with insufficient or missing data;~* Patients who do not give or are incapable of giving an informed consent;~* Patients who are not able or willing to travel to the center hospital for additional diagnostic procedures.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- If simple rules are conclusive (Type: OTHER): All patients included will undergo an ultrasound scan in which both the RMI and simple ultrasound-based rules are applied. This scan will take place in the hospital of inclusion. For 80% of all patients, this will be the only intervention.
- If simple rules are inconclusive (Type: OTHER): If the simple ultrasound-based rules, used in the first ultrasound scan, yield an inconclusive result (approx. 20% of all patients), patients are refered to the center hospital to undergo a second ultrasound (by an expert) and a DW-MRI scan. Furthermore, these group of patients will be asked to give an extra blood sample in order to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).